Literature DB >> 24371583

Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.

Guro Aune1, Astrid Kamilla Stunes1, Aina-Mari Lian2, Janne Elin Reseland2, Solveig Tingulstad3, Sverre H Torp4, Unni Syversen5.   

Abstract

Elevated serum levels of several cytokines have been reported in ovarian cancer. We have previously found a diagnostic and prognostic value of hepatocyte growth factor (HGF). The aims of this study were to evaluate the diagnostic and prognostic value of multiple serum cytokines in women with ovarian tumors, and to examine possible associations between serum levels of cytokines and the previously analyzed HGF. Preoperative levels of multiple cytokines were quantified by serum-based immunoassays in 113 women with a pelvic mass: 57 carcinomas, 23 borderline tumors, and 33 benign ovarian tumors. The results were related to clinicopathological parameters. Univariate and multivariate analyses of five-year overall survival were performed. The women with ovarian carcinoma had significantly higher preoperative serum levels of cancer antigen 125 (CA 125), interleukin 8 (IL-8), and plasminogen activator inhibitor-1 (PAI-1) than women with benign ovarian tumors. Serum IL-8 and PAI-1 levels were positively correlated to serum levels of HGF. In a multivariate analysis of five-year overall survival, IL-8 had a prognostic impact. Serum levels of IL-8 and PAI-1 were elevated in women with ovarian carcinoma compared to women with benign ovarian tumors, and positively correlated to serum HGF levels in women with ovarian tumors. IL-8 also seemed to have a prognostic impact.

Entities:  

Keywords:  Hepatocyte growth factor; Interleukin-8; Ovarian cancer; Plasma markers; Plasminogen activator inhibitor-1

Year:  2012        PMID: 24371583      PMCID: PMC3862343          DOI: 10.1016/j.rinim.2012.10.003

Source DB:  PubMed          Journal:  Results Immunol        ISSN: 2211-2839


  43 in total

1.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

2.  Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.

Authors:  C Seidel; M Børset; I Turesson; N Abildgaard; A Sundan; A Waage
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

3.  Plasma adiponectin and gastric cancer.

Authors:  Makoto Ishikawa; Joji Kitayama; Shinsuke Kazama; Takeyuki Hiramatsu; Kenji Hatano; Hirokazu Nagawa
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

4.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

5.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Authors:  Laura J Havrilesky; Clark M Whitehead; Jennifer M Rubatt; Robert L Cheek; John Groelke; Qin He; Douglas P Malinowski; Timothy J Fischer; Andrew Berchuck
Journal:  Gynecol Oncol       Date:  2008-06-27       Impact factor: 5.482

Review 6.  Clinical decision making using ovarian cancer risk assessment.

Authors:  Michael P Stany; G Larry Maxwell; G Scott Rose
Journal:  AJR Am J Roentgenol       Date:  2010-02       Impact factor: 3.959

7.  Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies.

Authors:  Eleni T Petridou; Nicholas Mitsiades; Spyros Gialamas; Miltiadis Angelopoulos; Alkistis Skalkidou; Nick Dessypris; Alex Hsi; Nikolaos Lazaris; Aristidis Polyzos; Constantinos Syrigos; Aoife M Brennan; Sofia Tseleni-Balafouta; Christos S Mantzoros
Journal:  Oncology       Date:  2008-04-17       Impact factor: 2.935

8.  Test of ovarian cancer multiplex xMAP technology panel.

Authors:  Jindra Vrzalova; Marketa Prazakova; Zdenek Novotny; Ondrej Topolcan; Miroslava Casova; Lubos Holubec
Journal:  Anticancer Res       Date:  2009-02       Impact factor: 2.480

9.  A serum based analysis of ovarian epithelial tumorigenesis.

Authors:  Brian Nolen; Adele Marrangoni; Liudmila Velikokhatnaya; Denise Prosser; Matthew Winans; Elesier Gorelik; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2008-11-12       Impact factor: 5.482

10.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

View more
  6 in total

1.  Plasma immune analytes in patients with epithelial ovarian cancer.

Authors:  Matthew S Block; Matthew J Maurer; Krista Goergen; Kimberly R Kalli; Courtney L Erskine; Marshall D Behrens; Ann L Oberg; Keith L Knutson
Journal:  Cytokine       Date:  2015-03-03       Impact factor: 3.861

Review 2.  Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer.

Authors:  Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

3.  Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.

Authors:  Moh Nailul Fahmi; Heru Pradjatmo; Indwiani Astuti; Ricvan Dana Nindrea
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

4.  Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum.

Authors:  WonJae Lee; Song Yi Ko; Muhaned S Mohamed; Hilary A Kenny; Ernst Lengyel; Honami Naora
Journal:  J Exp Med       Date:  2018-12-19       Impact factor: 14.307

5.  Parity History Determines a Systemic Inflammatory Response to Spread of Ovarian Cancer in Naturally Aged Mice.

Authors:  Ulises Urzua; Carlos Chacon; Luis Lizama; Sebastián Sarmiento; Pía Villalobos; Belén Kroxato; Katherine Marcelain; María-Julieta Gonzalez
Journal:  Aging Dis       Date:  2017-10-01       Impact factor: 6.745

Review 6.  The Emerging Role of Adiponectin in Female Malignancies.

Authors:  Luca Gelsomino; Giuseppina Daniela Naimo; Stefania Catalano; Loredana Mauro; Sebastiano Andò
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.